{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:27:17Z","timestamp":1792045637492,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T00:00:00Z","timestamp":1484524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/nm.4268","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T14:36:57Z","timestamp":1484577417000},"page":"185-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":514,"title":["Antibody 10-1074 suppresses viremia in HIV-1-infected individuals"],"prefix":"10.1038","volume":"23","author":[{"given":"Marina","family":"Caskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Schoofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Settler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Karagounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2330-8430","authenticated-orcid":false,"given":"Edward F","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4647-8566","authenticated-orcid":false,"given":"Nico","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago Y","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald H","family":"Learn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda Z","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gillor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Shimeliovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Unson-O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"K\u00fcmmerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeka","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi","family":"Witmer-Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Anthony P","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S","family":"Zingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy M","family":"Gulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Keler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J","family":"Bjorkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice H","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel C","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,16]]},"reference":[{"key":"BFnm4268_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1126\/science.1241144","volume":"341","author":"F Klein","year":"2013","unstructured":"Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199\u20131204 (2013).","journal-title":"Science"},{"key":"BFnm4268_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","volume":"28","author":"P Hraber","year":"2014","unstructured":"Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163\u2013169 (2014).","journal-title":"AIDS"},{"key":"BFnm4268_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","volume":"156","author":"AP West Jr.","year":"2014","unstructured":"West, A.P. Jr. et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633\u2013648 (2014).","journal-title":"Cell"},{"key":"BFnm4268_CR4","doi-asserted-by":"publisher","first-page":"e1001251","DOI":"10.1371\/journal.ppat.1001251","volume":"7","author":"I Mikell","year":"2011","unstructured":"Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).","journal-title":"PLoS Pathog."},{"key":"BFnm4268_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ni.3158","volume":"16","author":"DR Burton","year":"2015","unstructured":"Burton, D.R. & Mascola, J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571\u2013576 (2015).","journal-title":"Nat. Immunol."},{"key":"BFnm4268_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.chom.2016.02.002","volume":"19","author":"BF Haynes","year":"2016","unstructured":"Haynes, B.F. et al. HIV-host interactions: implications for vaccine design. Cell Host Microbe 19, 292\u2013303 (2016).","journal-title":"Cell Host Microbe"},{"key":"BFnm4268_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.tim.2014.12.007","volume":"23","author":"PL Moore","year":"2015","unstructured":"Moore, P.L., Williamson, C. & Morris, L. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 23, 204\u2013211 (2015).","journal-title":"Trends Microbiol."},{"key":"BFnm4268_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/aid.1994.10.359","volume":"10","author":"A Buchacher","year":"1994","unstructured":"Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359\u2013369 (1994).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BFnm4268_CR9","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/JVI.67.11.6642-6647.1993","volume":"67","author":"T Muster","year":"1993","unstructured":"Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642\u20136647 (1993).","journal-title":"J. Virol."},{"key":"BFnm4268_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406\u2013412 (2012).","journal-title":"Nature"},{"key":"BFnm4268_CR11","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109, E3268\u2013E3277 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"BFnm4268_CR13","doi-asserted-by":"publisher","first-page":"236ra63","DOI":"10.1126\/scitranslmed.3008104","volume":"6","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 6, 236ra63 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4268_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2014.09.009","volume":"159","author":"F Garces","year":"2014","unstructured":"Garces, F. et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159, 69\u201379 (2014).","journal-title":"Cell"},{"key":"BFnm4268_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","volume":"326","author":"LM Walker","year":"2009","unstructured":"Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285\u2013289 (2009).","journal-title":"Science"},{"key":"BFnm4268_CR16","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J.F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"BFnm4268_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"BFnm4268_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature12053","volume":"496","author":"HX Liao","year":"2013","unstructured":"Liao, H.X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469\u2013476 (2013).","journal-title":"Nature"},{"key":"BFnm4268_CR20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.celrep.2014.04.001","volume":"7","author":"L Scharf","year":"2014","unstructured":"Scharf, L. et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7, 785\u2013795 (2014).","journal-title":"Cell Rep."},{"key":"BFnm4268_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature13601","volume":"515","author":"J Huang","year":"2014","unstructured":"Huang, J. et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138\u2013142 (2014).","journal-title":"Nature"},{"key":"BFnm4268_CR22","doi-asserted-by":"publisher","first-page":"15859","DOI":"10.1073\/pnas.1213409109","volume":"109","author":"J Pietzsch","year":"2012","unstructured":"Pietzsch, J. et al. A mouse model for HIV-1 entry. Proc. Natl. Acad. Sci. USA 109, 15859\u201315864 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR23","doi-asserted-by":"publisher","first-page":"18921","DOI":"10.1073\/pnas.1214785109","volume":"109","author":"B Moldt","year":"2012","unstructured":"Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109, 18921\u201318925 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105\u2013109 (2016).","journal-title":"Nature"},{"key":"BFnm4268_CR25","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1084\/jem.20132494","volume":"211","author":"M Shingai","year":"2014","unstructured":"Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061\u20132074 (2014).","journal-title":"J. Exp. Med."},{"key":"BFnm4268_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118\u2013122 (2012).","journal-title":"Nature"},{"key":"BFnm4268_CR27","doi-asserted-by":"publisher","first-page":"16538","DOI":"10.1073\/pnas.1315295110","volume":"110","author":"JA Horwitz","year":"2013","unstructured":"Horwitz, J.A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA 110, 16538\u201316543 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D.H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"BFnm4268_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277\u2013280 (2013).","journal-title":"Nature"},{"key":"BFnm4268_CR30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","volume":"158","author":"A Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989\u2013999 (2014).","journal-title":"Cell"},{"key":"BFnm4268_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"BFnm4268_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243\u20131253 (2014).","journal-title":"Cell"},{"key":"BFnm4268_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"CL Lu","year":"2016","unstructured":"Lu, C.L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"BFnm4268_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"BFnm4268_CR35","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R.M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"BFnm4268_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","volume":"182","author":"JE Ledgerwood","year":"2015","unstructured":"Ledgerwood, J.E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289\u2013301 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnm4268_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"BFnm4268_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J.F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"BFnm4268_CR39","doi-asserted-by":"publisher","first-page":"W213","DOI":"10.1093\/nar\/gkv404","volume":"43","author":"H Yoon","year":"2015","unstructured":"Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43, W213\u2013W219 (2015).","journal-title":"Nucleic Acids Res."},{"key":"BFnm4268_CR40","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108\u201310125 (2005).","journal-title":"J. Virol."},{"key":"BFnm4268_CR41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman, M.S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439\u20131452 (2010).","journal-title":"J. Virol."},{"key":"BFnm4268_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"BFnm4268_CR43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer, R.J., Huitema, A.D., Schellens, J.H. & Beijnen, J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493\u2013507 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnm4268_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nri2524","volume":"9","author":"S Moir","year":"2009","unstructured":"Moir, S. & Fauci, A.S. B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235\u2013245 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnm4268_CR45","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nsmb.3291","volume":"23","author":"HB Gristick","year":"2016","unstructured":"Gristick, H.B. et al. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 23, 906\u2013915 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnm4268_CR46","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1128\/JVI.00915-10","volume":"84","author":"ME Abram","year":"2010","unstructured":"Abram, M.E., Ferris, A.L., Shao, W., Alvord, W.G. & Hughes, S.H. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 84, 9864\u20139878 (2010).","journal-title":"J. Virol."},{"key":"BFnm4268_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin, J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483\u2013489 (1995).","journal-title":"Science"},{"key":"BFnm4268_CR48","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1128\/JVI.01225-12","volume":"87","author":"F Maldarelli","year":"2013","unstructured":"Maldarelli, F. et al. HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J. Virol. 87, 10313\u201310323 (2013).","journal-title":"J. Virol."},{"key":"BFnm4268_CR49","doi-asserted-by":"publisher","first-page":"8540","DOI":"10.1128\/JVI.00522-15","volume":"89","author":"S Zhou","year":"2015","unstructured":"Zhou, S., Jones, C., Mieczkowski, P. & Swanstrom, R. Primer ID validates template sampling depth and greatly reduces the error rate of next-generation sequencing of HIV-1 genomic RNA populations. J. Virol. 89, 8540\u20138555 (2015).","journal-title":"J. Virol."},{"key":"BFnm4268_CR50","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/nm.3963","volume":"21","author":"JN Bhiman","year":"2015","unstructured":"Bhiman, J.N. et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21, 1332\u20131336 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4268_CR51","doi-asserted-by":"crossref","unstructured":"Laird Smith, M. et al. Rapid Sequencing of Complete env Genes from Primary HIV-1 Samples. in Virus Evolution (Oxford University Press, 2016).","DOI":"10.1093\/ve\/vew018"},{"key":"BFnm4268_CR52","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K.J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4268_CR53","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1128\/JVI.03608-14","volume":"89","author":"RM Lynch","year":"2015","unstructured":"Lynch, R.M. et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89, 4201\u20134213 (2015).","journal-title":"J. Virol."},{"key":"BFnm4268_CR54","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1073\/pnas.1309215110","volume":"110","author":"AP West Jr.","year":"2013","unstructured":"West, A.P. Jr. et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl. Acad. Sci. USA 110, 10598\u201310603 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nm1244","volume":"11","author":"A Trkola","year":"2005","unstructured":"Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615\u2013622 (2005).","journal-title":"Nat. Med."},{"key":"BFnm4268_CR56","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1128\/JVI.00110-09","volume":"83","author":"MD Simek","year":"2009","unstructured":"Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337\u20137348 (2009).","journal-title":"J. Virol."},{"key":"BFnm4268_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i14","volume":"25","author":"SJ Ratcliffe","year":"2008","unstructured":"Ratcliffe, S.J. & Shults, J. GEEQBOX: A MATLAB toolbox for generalized estimating equations and quasi-least squares. J. Stat. Softw. 25, 1\u201314 (2008).","journal-title":"J. Stat. Softw."},{"key":"BFnm4268_CR58","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1128\/JVI.02660-07","volume":"82","author":"JF Salazar-Gonzalez","year":"2008","unstructured":"Salazar-Gonzalez, J.F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952\u20133970 (2008).","journal-title":"J. Virol."},{"key":"BFnm4268_CR59","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","volume":"23","author":"MA Larkin","year":"2007","unstructured":"Larkin, M.A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947\u20132948 (2007).","journal-title":"Bioinformatics"},{"key":"BFnm4268_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/sysbio\/syq010","volume":"59","author":"S Guindon","year":"2010","unstructured":"Guindon, S. et al. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307\u2013321 (2010).","journal-title":"Syst. Biol."},{"key":"BFnm4268_CR61","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nmeth.2109","volume":"9","author":"D Darriba","year":"2012","unstructured":"Darriba, D., Taboada, G.L., Doallo, R. & Posada, D. jModelTest 2: more models, new heuristics and parallel computing. Nat. Methods 9, 772 (2012).","journal-title":"Nat. Methods"},{"key":"BFnm4268_CR62","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/bioinformatics\/btu033","volume":"30","author":"A Stamatakis","year":"2014","unstructured":"Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30, 1312\u20131313 (2014).","journal-title":"Bioinformatics"},{"key":"BFnm4268_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jviromet.2007.02.015","volume":"143","author":"JL Kirchherr","year":"2007","unstructured":"Kirchherr, J.L. et al. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 143, 104\u2013111 (2007).","journal-title":"J. Virol. Methods"},{"key":"BFnm4268_CR64","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B.F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4268_CR65","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh, K. & Standley, D.M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772\u2013780 (2013).","journal-title":"Mol. Biol. Evol."},{"key":"BFnm4268_CR66","doi-asserted-by":"publisher","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","volume":"5","author":"MN Price","year":"2010","unstructured":"Price, M.N., Dehal, P.S. & Arkin, A.P. FastTree 2\u2014approximately maximum-likelihood trees for large alignments. PLoS One 5, e9490 (2010).","journal-title":"PLoS One"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.4268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4268","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:00:20Z","timestamp":1684436420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.4268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,16]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFnm4268"],"URL":"https:\/\/doi.org\/10.1038\/nm.4268","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,16]]},"assertion":[{"value":"16 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Keler is employed by Celldex Therapeutics. 10-1074 was manufactured by Celldex Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}